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Abstract
Objective—To measure tenofovir (TFV) concentrations in the male genital tract (GT) after single
and multiple doses of tenofovir disoproxil fumarate (TDF) and evaluate the HIV-1 RNA response
to monotherapy.
Design and Methods—A pharmacokinetic study of blood plasma (BP) and GT TFV
concentrations in 9 men was conducted after 1 and ≥14 doses of TDF. TFV concentrations were
measured by validated high-performance liquid chromatography–ultraviolet or tandem mass
spectrometry methods, and HIV-1 RNA was measured using Roche (Roche Molecular Systems,
Branchburg, NJ) or bioMerieux (bioMerieux, Durham, NC) kits.
Results—TFV GT concentrations were 4.4-fold ± 5.1-fold higher than BP after dose 1 and 5.1-fold
± 6.8-fold higher than BP after dose 14. Intracellular GT TFV-diphosphate concentrations were 9.4-
fold higher than BP after dose 1 and 17.5-fold ± 22.6-fold higher after dose 7. After 14 days of TDF
monotherapy, HIV-1 RNA decreased by 0.9 log10 copies/mL in blood and 1.0 log10 copies/mL in
the GT.
Conclusions—High TFV concentrations were achieved rapidly in the GT of all subjects after
single and multiple doses and potently reduced BP and GT HIV-1 RNA levels.
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Approximately 40 million people worldwide are currently living with HIV/AIDS, most of
whom have been infected through sexual contact.1 The risk of sexual transmission of HIV
increases with increasing HIV RNA concentrations in the genital tract (GT) of men and women.
2-4 Evidence also suggests that the male GT may serve as a reservoir for HIV replication.5
Thus, antiretrovirals (ARVs) that effectively penetrate into the genital compartment may
reduce viral replication locally, reduce the risk of sexual transmission of HIV, and assist in
decreasing the development of drug-resistant virus.
Tenofovir disoproxil fumarate (TDF) is the orally bioavailable form of tenofovir (TFV), which
is converted intracellularly to TFV-diphosphate, a potent inhibitor of HIV reverse transcriptase.
TFV has been shown to prevent simian immunodeficiency virus (SIV) infection in monkey
models after vaginal inoculation. Early intervention with subcutaneous TFV (≤36 hours after
vaginal inoculation with HIV-2) was effective in preventing infection in macaques.6 These
data suggest that TFV may have an active role in pre-exposure prophylaxis (PREP) and
postexposure prophylaxis (PEP) regimens, which may be explained by TFV’s ability to
penetrate the female GT quickly and effectively.7 However, the effectiveness of TFV to
penetrate the male GT and its capacity to decrease viral shedding in semen are currently
unknown.
In this study, we describe first-dose and steady-state extracellular drug exposure to TFV in the
GT as compared with blood plasma (BP), evaluate intracellular drug exposure of TFV-
diphosphate, and measure the ability of TFV to suppress GT HIV-1 RNA acutely in individuals




Subjects were recruited from the Infectious Disease Clinic at the University of North Carolina
(UNC) at Chapel Hill between January 2003 and May 2005. Men were eligible for enrollment
if they were HIV-1 infected, ≥18 years of age, and had a plasma HIV-1 RNA level >200 copies/
mL. Subjects were not currently taking any ARV medications or were on a stable yet
incompletely suppressive ARV regimen with no plans for altering that regimen for at least 1
month. Potential participants were excluded if they were unable to abstain from sexual
intercourse for 48 hours before study visits, had an estimated drug adherence rate of, <80%,
had a creatinine clearance (ClCr) <60 mL/min, weighed ≤50 kg, had an active genital or
systemic infection, or had a hematocrit measurement <30%.
All participants gave written informed consent before study participation. This protocol was
approved by the Biomedical Institutional Review Board of the University of North Carolina
at Chapel Hill.
Study Design and Procedures
All inpatient and outpatient visits were performed at the Verne S. Caviness General Clinical
Research Center located within the UNC Memorial Hospital. Subjects were required to
continue their current stable ARV therapy, with the addition of TDF at a dosage of 300 mg/d
for 28 days or to initiate TDF monotherapy at a dosage of 300 mg for 14 days before being
placed on highly active antiretroviral therapy (HAART). For the duration of the study, subjects
recorded the exact time of TDF administration on a study drug diary card and were interviewed
as to their medication adherence at each study visit.
All subjects were advised to abstain from sexual intercourse for 48 hours before each visit.
Subjects were expected to donate semen with a matching blood sample at each of the outpatient
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visits. On days 1, 3, 5, and 7, 24-hour postdose blood plasma (BP) and GT samples were taken.
During the intensive pharmacokinetic (PK) visit on day 14, blood samples were taken at 0, 1,
2, 3, 4, 5, 6, 8, 12, and 24 hours after dosing, whereas GT samples were taken at 0 and 12 hours.
Men who were receiving other ARVs in addition to TDF also had PK samples taken at times
0, 4, 10, and 24 hours after dosing on 4 separate outpatient visits anytime from days 14 to 28.
At the end of the dosing interval, and just before administering the dose within which a seminal
sample would be collected, men were asked to empty and discard the contents of the seminal
compartment by masturbation and ejaculation.
Sample Processing
Blood samples used for extracellular analysis were collected in ethylenediaminetetraacetic acid
(EDTA)–containing tubes and were kept on ice for no more than 60 minutes before plasma
was separated by centrifugation at 2600 rpm for 15 minutes at 4°C. Plasma was aliquoted into
cryovials and frozen at −80°C until analysis. Peripheral blood mononuclear cells (PBMCs)
were isolated using CPT (Becton-Dickinson, Franklin Lakes, NJ) tubes containing sodium
citrate. The CPT tube, containing 8 mL of whole blood, was centrifuged at 2700 rpm for 20
minutes at room temperature. The contents of the CPT tube, isolated above the gel, were poured
into a 15-mL conical tube. Approximately 2 mL of phosphate-buffered saline (PBS) was added
to the CPT tube to resuspend any remaining monocytes and was then added to the 15-mL
conical tube. PBS was added to the conical tube to bring the total volume to 15 mL. The conical
tube was then centrifuged at 1300 rpm at room temperature for 10 minutes. The supernatant
was discarded, and the cell pellet was resuspended in 100 μL of PBS and placed on ice.
Mononuclear cells were counted using a hemocytometer with trypan blue exclusion.
Remaining cells were lysed for approximately 15 minutes with 200 μL of 100% methanol. Cell
debris was removed by centrifugation at 4°C for 15 minutes at 3000 rpm. The supernatant was
transferred to a cryovial and stored at −80°C until analysis.
Semen samples were left to liquefy at room temperature for 30 minutes and then centrifuged
for 20 minutes at between 2000 and 2600 rpm in a conical tube at 4°C. Seminal plasma was
separated into 75-μL and 200-μL aliquots for HIV-1 RNA and drug concentration analyses
and stored at −80°C. The cell pellet was resuspended in 8 mL of PBS, layered onto 4 mL of
Percoll (Sigma-Aldrich, St. Louis, MO), and centrifuged at 2000 rpm for 20 minutes at room
temperature. The seminal mononuclear cells found at the interface between the PBS and Percoll
(top 2 layers) were carefully removed, placed in 10 mL of PBS, and centrifuged, and the cell
pellet was resuspended to 100 μL. Mononuclear cells were counted using a hemocytometer
and trypan blue exclusion. Cells were lysed for approximately 15 minutes with 200 μL of 100%
methanol. Cell debris was removed by centrifugation for 15 minutes at 3000 rpm at 4°C. The
supernatant was aliquoted into cryovials and stored at −80°C until analysis.
Tenofovir Quantification
Extracellular TFV concentrations in BP and seminal plasma (SP) were quantitated at the UNC
Center for AIDS Research (CFAR) Clinical Pharmacology and Analytical Chemistry Core
using validated liquid chromatography (LC)/ultraviolet (UV)8 methods. Intraday and interday
precision were 3.7% and 5.2%, respectively, and the lower limit of quantification (LLOQ) was
10 ng/mL. Cellular lysates were sent to Gilead Sciences (Durham, NC) for quantification of
TFV-diphosphate using a validated LC–tandem mass spectrometry (MS/MS) method.9
Within-run accuracy (% error) values ranged from 1.3% to 14.5%, and precision (% relative
standard deviation [RSD]) values ranged from 0.01% to 10.9% for TFV-diphosphate, carbovir
triphosphate, and lamivudine triphosphate. Between-run accuracy (% error) values ranged
from 20.7% to 13.9%, and precision (% RSD) values ranged from 2.5% to 7.9% for the 3
compounds. All calculated values for quality control samples fell within industry guidelines
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of 20% for the LLOQ and 15% for the upper limit of quantitation. The LLOQ was 15 fmol/
106 cells.
HIV-1 RNA Determinations
BP HIV-1 RNA was quantified with the Roche Amplicor HIV-1 Monitor UltraSensitive assay
(version 1.5; Roche Molecular Systems, Branchburg, NJ). The quantification of HIV-1 RNA
in the SP was performed with the bioMerieux NucliSens HIV-1 QT assay (bioMerieux,
Durham, NC).10 The limits of quantitation for the Roche Amplicor HIV-1 Monitor
UltraSensitive and the bioMerieux NucliSens HIV-1 QT assay are 50 copies/mL and 400
copies/mL, respectively. All BP and GT samples that were determined as having an HIV-1
RNA level >1000 copies/mL at day 14 were genotyped to assess whether the K65R mutation
was present. The determination of HIV-1 RNA and viral genotype was performed by the UNC
CFAR Virology Core.
Data Analysis and Statistical Methods
Blood and GT results were grouped according to time after TDF ingestion. Mean extracellular
and intracellular GT/BP concentration ratios were calculated among matched pairs in all
subjects. The area under the time-concentration curve (AUC0–τ) was calculated for BP using
WinNonlin (version 4.0.1; Pharsight, Mountain View, CA). A comparison of BP and GT results
was calculated using STATA (version 8.0; StataCorp LP, College Station, TX). HIV-1 RNA
values below the limit of quantification in GT and BP were assigned values of 399 copies/mL
and 49 copies/mL, respectively. The mean changes in BP and GT HIV-1 RNA level and blood
CD4 cell count were calculated between day 14 and baseline. TFV extracellular and
intracellular concentrations are expressed as mean (ng/mL for extracellular concentrations and




Nine men were enrolled in the study. Eight men received TDF as monotherapy, and 1 man
received TDF intensification added to a nonsuppressive ARV regimen. Non-Hispanic blacks
accounted for most of the subjects (67%). Subject demographics are described in Table 1.
Extracellular Tenofovir Concentrations in the Genital Tract
Figure 1 displays the BP and SP TFV concentrations from a first-dose to steady-state condition.
After a single dose, TFV rapidly and effectively penetrated into SP. On day 1, the extracellular
TFVGT/BP concentration at 24 hours (C24h) ratio was 4.4 ± 5.1. At steady state, TFV continued
to penetrate into SP effectively. The extracellular TFV GT/BP concentration ratio at the end
of the dosing interval was 5.1 ± 6.8.
Intracellular Tenofovir Concentrations in the Genital Tract
Seminal mononuclear cell yields ranged from 1.0 × 105 to 5.2 × 106. Because of low
mononuclear cell yields (<106 cells per sample), TFV-diphosphate concentrations could not
be detected in 6 of the 9 men. Although an association was noted between frequency of semen
sample collection and seminal volume (r2 = 0.75), no association was found between seminal
volume or frequency of semen collection and seminal leukocyte yield (r2 = 0.04) that might
explain these undetectable concentrations. For those in whom intracellular TFV-diphosphate
could be detected, mean GT and PBMC concentrations were 1544 ± 2079 and 118 ± 59 fmol/
106 cells, respectively. Mean GT/BP C24h ratios after the first, fifth, and seventh doses of TDF
(the first week of therapy) were 9.4, 8.0, and 17.5, respectively.
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For men receiving 14 days of TDF monotherapy and who had complete paired BP and GT
samples, HIV-1 RNA levels were reduced by a geometric mean of 0.9 log10 copies/mL (BP)
and 1.0 log10 copies/mL (GT), respectively. For these men, the median HIV-1 RNA levels
after 14 days in BP and GT were 866 copies/mL and <400 copies/mL, respectively. A mean
increase in CD4 count of 31 ± 89 cells/μL (range: 62 to 150 cells/μL) was observed over 14
days in subjects receiving TDF monotherapy. The HIV-1 RNA in the GT was initially
suppressed (<400 copies/mL) and remained so for the duration of the study in the 1 man on
TDF intensification. His HIV-1 RNA level in BP was 366 copies/mL at baseline and 709
copies/mL by day 28 of TDF intensification. No K65R mutations were seen in any of the BP
(n = 4) or GT (n = 1) samples having an HIV-1 RNA level >1000 copies/mL at the end of the
study period.
DISCUSSION
The effectiveness of ARV therapy for the prevention of sexual transmission of HIV may rely
on the capacity of ARVs to accumulate in sanctuary sites, such as the GT,11,12 allowing for
maximal suppression of HIV RNA replication. In this study, TFV successfully and rapidly
penetrated the GT with concentrations reaching up to 19.1 times those concurrently found in
BP. In the 3 subjects in whom intracellular concentrations of TFV-diphosphate, TDF’s active
metabolite, were successfully measured, these concentrations were also higher in seminal
mononuclear cells compared with PBMCs. This is an important finding and not uniform across
the nucleoside/nucleotide reverse transcriptase inhibitors that have been investigated to date.
Only zidovudine and lamivudine triphosphate have been previously measured in seminal
mononuclear cells. Although zidovudine and lamivudine achieve extracellular GTexposures
4- to 6-fold higher than BP, intracellular triphosphate concentrations are lower (zidovudine)
or similar (lamivudine) to concentrations in PBMCs.13 This divergence in exposure may be
attributable to different kinase activities or cellular activation in the 2 compartments, since
zidovudine is preferentially phosphorylated in activated cells and lamivudine is preferentially
phosphorylated in quiescent cells.14 In contrast, TFV is able to be phosphorylated in activated
and resting cells,15 which may result in higher TFV-diphosphate concentrations in the male
GT. The extracellular and intracellular GT concentrations for TFV are the highest, relative to
BP, among the ARVs investigated to date.13,16-21
Two important characteristics are questioned when evaluating an ARV agent’s potential role
in decreasing the infectiousness of HIV-1: the antiviral effect and the evolution of resistance
within the GT. This is the first study to evaluate the antiviral response in the human GT with
TDF monotherapy. We found an equally potent virologic response (approximately a 1.0-log
decline in HIV-1 RNA) in the GT and BP in subjects after receiving 14 days of TDF
monotherapy. This potent and rapid compartmental virologic response suggests that the
probability of further sexual transmission of HIV from men to their partners is reduced, because
HIV-1 RNA concentrations within the GT serve as a surrogate marker for infectiousness.2,3,
16 Second, ARV monotherapy is traditionally associated with the development of resistance.
The 4 patients with BP HIV-1 RNA levels >1000 copies/mL and the 1 patient with a GT HIV-1
RNA level >1000 copies/mL after 14 days of monotherapy did not develop the K65R mutation,
however, which is consistent with a previous investigation that dosed TDF monotherapy for
21 days.22
Only 1 other study (ACTG 850) has characterized drug concentrations and viral response to
ARV monotherapy in BP and GT secretions.16 This evaluation of 19 men receiving amprenavir
monotherapy at a dose of 1200 mg twice daily obtained single random samples of BP and GT
secretions for drug concentration analysis. Eight men responded in BP and SP, 8 of 19
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responded in SP only, and 3 of 19 did not respond in SP or BP. Differences in sampling
strategies for PK and HIV-1 RNA response preclude making comparisons with the current
study, however.
In summary, the increased concentration of TFV in its active form may explain the potent and
rapid reduction of HIV-1 concentration observed in the male GT. Because HIV-1 RNA
concentrations in BP may not be as reliable a predictor of RNA concentrations in the GT,23
we believe these results to be important as they relate to the potential of TDF to reduce the
sexual transmission of HIV.
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A, TFV concentrations in SP and BP on day 1 and steady state (mean ± SE). B, Trough TFV
concentrations in SP and BP on days 1, 3, 5, and 7 (mean + SE).
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TABLE 1
Patient Demographics at Baseline
Demographics n = 9 Men Mean SD
Age (y) 39.9 6.0
Plasma HIV RNA level (log10 copies/mL)
* 4.4 0.6
GT HIV RNA level (log10 copies/mL)
* 3.2 0.7
CD4 count (cells/μL)* 353 403
Race/ethnicity 6 (66.7%) African American
3 (33.3%) white
*
Male patient on TDF intensification not included.
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